Older people are at a greater risk of medicine-induced toxicity resulting from either
increased drug sensitivity or age-related pharmacokinetic changes. The scenario is further …

Alzheimer's disease (AD) is a neurodegenerative disorder, characterized by β-amyloid
plaques and hyperphosphorylated tau tangles in the brain. Alongside these pathological …

The human blood‐brain barrier (BBB) transporter P‐gp can efflux amyloid‐β (Aβ) out of the
central nervous system (CNS). Aβ is thought to be the causative agent for Alzheimer's …

Pathophysiological impairment of the neurovascular unit, including the integrity and
dynamics of the blood-brain barrier (BBB), has been denoted both a cause and …

The successful treatment of Alzheimer's disease (AD) will require drugs that can negotiate
the blood–brain barrier (BBB). However, the BBB is not simply a physical barrier, but a …

Purpose The purpose of this study was to systematically assess the impact of Alzheimer's
disease (AD)-associated blood–brain barrier (BBB) alterations on the uptake of therapeutics …

During neurodegenerative and neuroinflammatory disorders of the central nervous system
(CNS), such as Alzheimer's disease (AD) and multiple sclerosis (MS), the protective function …

The blood–brain barrier (BBB) expresses a high abundance of transporters, particularly P‐
glycoprotein (P‐gp), that regulate endogenous and exogenous molecule uptake and …

The blood-brain barrier (BBB) not only impedes the influx of intravascular substances from
blood to brain, but also promotes transport of substances from blood to brain or from brain to …

Protection of the brain is strengthened by active transport and ABC transporters. P-
glycoprotein (P-gp) at the blood-brain barrier (BBB) functions as an active efflux pump by …